Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Gossamer Bio is a clinical-stage biopharmaceutical company whose value is almost entirely dependent on its lead drug candidate, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</li>
 <li>The pivotal Phase 3 PROSERA trial for seralutinib in PAH has completed enrollment, with topline data expected in February 2026. This is the single most significant catalyst for the company.</li>
 <li>Financially, the company operates at a net loss, burning cash to fund R&amp;D. However, its current cash reserves are expected to fund operations into the first half of 2027, beyond the anticipated PROSERA data readout.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Gossamer Bio is a clinical-stage biopharmaceutical company whose value is almost entirely dependent on its lead drug candidate, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
  The pivotal Phase 3 PROSERA trial for seralutinib in PAH has completed enrollment, with topline data expected in February 2026. This is the single most significant catalyst for the company.
  Financially, the company operates at a net loss, burning cash to fund R&amp;D. However, its current cash reserves are expected to fund operations into the first half of 2027, beyond the anticipated PROSERA data readout.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Gossamer Bio Inc (GOSS US) - Oct 2025

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Navan is offering 36.9mm shares at $24-$26 and will debut on October 31st invoking a 20-day effectiveness rule during the current government shutdown.</li>
<li>Their revenue grew 33% year-over-year from $402 million in fiscal 2024 to $537 million in fiscal 2025.</li>
<li>Navan (formerly TripActions) is led by two high-profile co-founders who previously sold had a business acquired in this space.</li>
</ul>


Navan is offering 36.9mm shares at $24-$26 and will debut on October 31st invoking a 20-day effectiveness rule during the current government shutdown.
Their revenue grew 33% year-over-year from $402 million in fiscal 2024 to $537 million in fiscal 2025.
Navan (formerly TripActions) is led by two high-profile co-founders who previously sold had a business acquired in this space.


Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

MapLight Therapeutics / Equity Capital Markets

<ul>
<li>Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. </li>
<li>Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. </li>
<li>The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.</li>
</ul>


Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. 
Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. 
The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.


Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

<ul><li>Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trials</li><li>Recent changes in C-suite, insider stock purchases, and partnerships with pharmaceutical companies</li><li>Company has ample cash and near-term catalysts for high upside potential in treating PAH, a serious hemodynamic disorder.</li></ul>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trialsRecent changes in C-suite, insider stock purchases, and partnerships with pharmaceutical companiesCompany has ample cash and near-term catalysts for high upside potential in treating PAH, a serious hemodynamic disorder.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Gossamer Bio Inc (GOSS) - Monday, Aug 26, 2024

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>The weight of the evidence suggests that the lows for this bear market have likely already been established, but that does not mean it will be smooth sailing from here.</li>
<li>The SPX and NDX are both testing important resistance levels (4165-4180 and the YTD downtrend, respectively), making this a logical spot for the indexes to stall and potentially pull back.</li>
<li>Ultimately, we would expect to see support near their 50-day MAs as the market goes through a bottoming process. We remain neutral overall.</li>
</ul>


The weight of the evidence suggests that the lows for this bear market have likely already been established, but that does not mean it will be smooth sailing from here.
The SPX and NDX are both testing important resistance levels (4165-4180 and the YTD downtrend, respectively), making this a logical spot for the indexes to stall and potentially pull back.
Ultimately, we would expect to see support near their 50-day MAs as the market goes through a bottoming process. We remain neutral overall.


S&P 500, Nasdaq 100 Testing Key Resistance Levels; Pause Likely; Buying Biotech

United States

Gossamer Bio, Inc. operates as a biopharmaceutical company. The Company focuses on discovering, acquiring, and developing therapeutics in the disease areas of immunology, inflammation, and oncology. Gossamer Bio serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gossamer Bio Inc (GOSS US)

Primer: Gossamer Bio Inc (GOSS US) - Oct 2025

Gossamer Bio is a clinical-stage biopharmaceutical company whose value is almost entirely dependent on its lead drug candidate, seralutinib, for...

αSK

Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Gossamer Bio Inc (GOSS) - Monday, Aug 26, 2024

Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trials. Recent changes in C-suite, insider stock purchases, and partnerships...

Value Investors Club (VIC)

S&P 500, Nasdaq 100 Testing Key Resistance Levels; Pause Likely; Buying Biotech

$SPX is testing important resistance in the 4165-4180 area, the same resistance level we were monitoring in early June before the market tumbled 13...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Gossamer Bio Inc (GOSS US) - Oct 2025

Gossamer Bio is a clinical-stage biopharmaceutical company whose value is almost entirely dependent on its lead drug candidate, seralutinib, for...

αSK

Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

​Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

​Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Gossamer Bio Inc (GOSS) - Monday, Aug 26, 2024

Gossamer Bio is developing seralutinib for PAH in Phase 3 clinical trials. Recent changes in C-suite, insider stock purchases, and partnerships...

Value Investors Club (VIC)

S&P 500, Nasdaq 100 Testing Key Resistance Levels; Pause Likely; Buying Biotech

$SPX is testing important resistance in the 4165-4180 area, the same resistance level we were monitoring in early June before the market tumbled 13...

Vermilion Research

Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...